Skip to main content
Advertisement
Neurology.org
Journals
Neurology
Clinical Practice
Genetics
Neuroimmunology & Neuroinflammation
Specialty Sites
COVID-19
Practice Current
Practice Buzz
Without Borders
Equity, Diversity and Inclusion
Innovations in Care Delivery
Collections
Topics A-Z
Residents & Fellows
Infographics
Patient Pages
Null Hypothesis
Translations
Podcast
CME
About
About the Journals
Contact Us
Editorial Board
Authors
Submit a Manuscript
Author Center
Advanced Search
Search for this keyword
Meeting abstracts only
Main menu
Neurology.org
Journals
Neurology
Clinical Practice
Genetics
Neuroimmunology & Neuroinflammation
Specialty Sites
COVID-19
Practice Current
Practice Buzz
Without Borders
Equity, Diversity and Inclusion
Innovations in Care Delivery
Collections
Topics A-Z
Residents & Fellows
Infographics
Patient Pages
Null Hypothesis
Translations
Podcast
CME
About
About the Journals
Contact Us
Editorial Board
Authors
Submit a Manuscript
Author Center
Home
Latest Articles
Current Issue
Past Issues
Residents & Fellows
User menu
Subscribe
My Alerts
Log in
Search
Search for this keyword
Meeting abstracts only
Advanced search
The most widely read and highly cited peer-reviewed neurology journal
Subscribe
My Alerts
Log in
Home
Latest Articles
Current Issue
Past Issues
Residents & Fellows
Tourbah
,
Ayman
et al
"24-Month-Treatment with-MD1003 (High Doses of Biotin) in Progressive Multiple Sclerosis: Results of the MS-SPI Trial Extension Phase (S49.004)."
Neurology
86
.
16 Supplement
(2016):
S49.004
.
Web. 24 Feb. 2021.
Citation Manager Formats
BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero